2
Registered trials
2
Recruiting
2
Unique sponsors
6
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
1
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Antibody-drug conjugate (ADC)
2 substances
PARP inhibitor
1 substance
Alkylating agent
1 substance
Phase I:
1
Phase I (First in Human):
1
Phase I
1 trial-
RecruitingBeOne Medicines AG CommercialIMP not specified
Phase I (First in Human)
1 trial-
RecruitingAstraZeneca AB Commercial[11C]AZ14193391; 6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL]-N-METHYLPYRIDINE-2-CARBOXAMIDE; DATOPOTAMAB DERUXTECAN; PALACAPARIB; TEMOZOLOMIDE; TRASTUZUMAB DERUXTECAN
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| BeOne Medicines AG | Commercial | 1 | Phase I | 1 |
| AstraZeneca AB | Commercial | 1 | Phase I (First in Human) | 1 |
New trials by year
2022
1
2025
1